About Alpha-1 DeficiencyThe Zemaira® DifferenceEffectivePureWell ToleratedConvenientPatient SupportOptimal DosingAlpha-1 Detection ResourcesZemaira® Patient Programs and ServicesOrdering Zemaira®Medical ResourcesImportant Safety InformationPrescribing InformationZemaira® for consumers

The Zemaira® Difference

Zemaira® is indicated for chronic augmentation and maintenance therapy in adults with alpha1-proteinase inhibitor (A1-PI) deficiency and clinical evidence of emphysema.

Support lungs. And patients.
  • Opposes neutrophil elastase post infusion3
  • Increases levels in epitherial lining fluid (ELF) with maintenance augmentation therapy3
Zemaira® is:

Pure

  • Zemaira® is the only Alpha-1 augmentation therapy approved by the FDA as highly purified.1,2,3

Convenient

  • Zemaira® has half or less the infusion time.*,3

Well Tolerated and Safe

  • During clinical trials, Zemaira® patients reported 6 times fewer infusion-related adverse events than Prolastin® patients.†
  • In a retrospective analysis of the pivotal clinical trial, Zemaira® patients were 3 times less likely to experience exacerbations of their COPD.

Supported

  • Programs and assistance for Alpha-1 patients. And their physicians.

* Based on recommended dosage as stated in the product package inserts of 60 mg/kg body weight at the infusion rate of 0.08 mL/kg/min.

† No clinically significant differences in adverse events were detected betwen the treatment groups.

Prolastin® is a registered trademark of Talecris Biotherapeutics, Inc.

Important Safety Information

Alpha1-Proteinase Inhibitor (Human), Zemaira is indicated for chronic augmentation and maintenance therapy for adults with alpha1-proteinase inhibitor (A1-PI) deficiency and emphysema. Clinical data demonstrating the long-term effects of chronic augmentation therapy with Zemaira are not available.

Zemaira may not be appropriate for the following adult individuals as they may experience severe reactions, including anaphylaxis: individuals with a known hypersensitivity and/or history of anaphylaxis or severe systemic reaction to A1-PI products or their components, and individuals with selective IgA deficiencies who have known antibodies against IgA.

In clinical studies, the following treatment-related adverse reactions were reported in 1% of subjects: asthenia (fatigue), injection-site pain, dizziness, headache, paresthesia (tingling), and pruritus (itching).

Zemaira is derived from human plasma. The risk of transmission of infectious agents, including viruses and, theoretically, the Creutzfeldt-Jakob disease (CJD) agent, cannot be completely eliminated.

Please see full prescribing information.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.

The information provided herein is solely for use by physicians and healthcare professionals in the United States. The CSL Behring product listed may not have been approved in other countries and may not be available everywhere.

  1. Prolastin® Alpha1-Proteinase Inhibitor (Human), Full Prescribing Information, January 2005.
  2. Aralast™ Alpha1-Proteinase Inhibitor (Human), Full Prescribing Information, January 2007.
  3. Data on file, CSL Behring LLC.